

PRESS RELEASE

Date: 20th December 2021

VaRi Bioscience GmbH announces that it will be presenting at ACCESS CHINA Biotech Forum@JPM WEEK 2022 during Jan 4th - Jan 13th, 2022.

Berlin, Germany, 20. December 2021 - VaRi Bioscience GmbH ("VaRi"), an innovative German biotech company focusing on novel drug delivery approaches in Female Health, announced today that it has been invited to showcase at ACCESS CHINA Biotech Forum@JPM WEEK 2022 during Jan 4th - Jan 13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the Western biopharma industry. The presentation has been arranged by YAFO Capital, Klaus Nickisch, Ph.D. and CEO of VaRi Bioscience GmbH will be hosting the presentation and answering questions from investors.

"ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the Western biopharma industry and the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations" explained Klaus Nickisch. „China considers Female Health one of the major important areas of drug research and we are confident that VaRi's innovative female specific drug delivery technology will be of great interest for Chinese companies and investors."

If investors are unable to make the live presentation, a replay day will be arranged one week later and a link will be posted to the Company's website.

About YAFO Capital Life Science

YAFO Capital Life Science is a Shanghai-based investment bank boutique and investment firm focused on Life Sciences. YAFO organizes every year ACCESS CHINA Forum events providing online corporate access through its proprietary deal-making platform, which covers 2.000+ BD directors and executives from Chinese biopharma, healthcare and investment firms.

For more Information, Please contact:

Klaus Nickisch, Ph.D. (CEO): +49 174 1510 148, knickisch@vari-bioscience.com

Kerstin Bode-Greuel, MD, PhD. (Head of BD): +49 170 5265 883, kbode-greuel@vari-bioscience.com

About VaRi Bioscience GmbH

VaRi Bioscience is an innovative German biotech company pioneering novel approaches to serve high unmet medical needs in various therapeutic areas of Female Health. The company focuses on the discovery, development and commercialization of innovative products centered around its unique, IP-protected approach of novel drug delivery concepts. www.vari-bioscience.com